Approval of new Alzheimer's drug in Canada called historic

The approval of a new drug that can slow the progress of Alzheimer ’s disease is being hailed as a historic moment in the treatment of a disease projected to affect one million Canadians by 2030. Article content

The drug, lecanemab, was approved by Health Canada this week. It is the first treatment available in Canada to focus on the underlying condition and not its symptoms. The treatment could be available to some Ottawa patients with mild cognitive impairment within a matter of months. Article content

Recommended Videos Article content

But amid excitement about long-awaited progress in the treatment of Alzheimer’s disease, there is some caution. Lecanemab is one of a group of drugs known as anti-amyloid therapies that may slow the progression of Alzheimer’s, but also carry serio